Susquehanna Fundamental Investments’s Sage Therapeutics SAGE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-196,284	Closed	-$1.79M	–	738
2025 Q2	$1.79M	Sell	196,284 -15,279	-7%	-$112K	0.05%	355
2025 Q1	$1.68M	Sell	211,563 -4,308	-2%	-$31.5K	0.02%	561
2024 Q4	$1.17M	Buy	+215,871	New	+$1.32M	0.02%	668
2021 Q2	–	Sell	-37,626	Closed	-$2.82M	–	1765
2021 Q1	$2.82M	Buy	+37,626	New	+$3.08M	0.05%	520

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna Fundamental Investments's SAGE Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 196,284 shares — an estimated $1.79M sold.

Susquehanna Fundamental Investments first reported a position in SAGE in Q1 2021 and held it in 4 quarters. The position peaked at $2.82M in Q1 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Susquehanna Fundamental Investments reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 196,284 Sage Therapeutics shares in Q3 2025, an estimated $1.79M.
Susquehanna Fundamental Investments first reported a position in Sage Therapeutics in Q1 2021 and held it in 4 quarters.
Susquehanna Fundamental Investments's Sage Therapeutics position peaked at $2.82M in Q1 2021.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.